阿尔茨海默病病因及发病机制研究进展

doi:10.6040/j.issn.1671-7554.0.2017.318

摘要/Abstract

摘要： 阿尔茨海默病(AD)是一种主要侵袭老年人群的神经系统变性病,也是老年期痴呆的最主要原因。本病特征性的临床表现为进行性的认知功能障碍,最终导致罹患者的社会功能全面丧失。AD的病因和发病机制非常复杂,目前尚未得到充分阐明,从而严重阻碍了有效的AD防治策略的开发。本文结合相关研究领域最新进展,对AD危险因素及其主要发病机制的假说进行总结。

关键词: 阿尔茨海默病, 病因, 危险因素, 痴呆, 发病机制

Abstract: Alzheimers disease(AD)is a neurodegenerative disease majorly attacking aging population. AD is the most common type of aging-related dementia, featured by irreversible cognitive impairments and loss of social function. The 山东大学学报 (医学版)55卷10期 -杜蘅,等.阿尔茨海默病病因及发病机制研究进展 \=-etiology and pathogenesis of AD have not been fully elucidated yet, which significantly deters the development of strategies for AD prevention and treatment. Here, in summary of the up-to-date research progress, we reviewed the risk factors for AD as well as the mechanisms of the pathogenesis of this neurological disorder.

Key words: Etiology, Pathogenesis, Alzheimers disease, Dementia, Risk factors

中图分类号:

R741.02

杜蘅,袁晓东. 阿尔茨海默病病因及发病机制研究进展[J]. 山东大学学报（医学版）, 2017, 55(10): 21-27.

DU Heng, YUAN Xiaodong. Progress in the etiology and pathogenesis of Alzheimers disease[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 21-27.

参考文献

[1] Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers[J]. Biochem Pharmacol, 2014, 88(4): 640-651.
[2] Erikson GA, Bodian DL, Rueda M, et al. Whole-genome sequencing of a healthy aging cohort[J]. Cell, 2016,165(4): 1002-1011.
[3] Neill D. Should Alzheimers disease be equated with human brain ageing? A maladaptive interaction between brain evolution and senescence[J]. Ageing Res Rev, 2012, 11(1): 104-122.
[4] Kim S, Kim MJ, Kim S, et al. Gender differences in risk factors for transition from mild cognitive impairment to Alzheimers disease: A CREDOS study[J]. Compr Psychiatry, 2015, 62: 114-122. doi: 10.1016/j.comppsych.2015.07.002.
[5] Xia D, Watanabe H, Wu B, et al. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimers disease[J]. Neuron, 2015, 85(5): 967-981.
[6] Karch CM, Goate AM. Alzheimers disease risk genes and mechanisms of disease pathogenesis[J]. Biol Psychiatry, 2015, 77(1): 43-51.
[7] Podlesniy P, Llorens F, Golanska E, et al. Mitochondrial DNA differentiates Alzheimers disease from Creutzfeldt-Jakob disease[J]. Alzheimers Dement, 2016, 12(5): 546-555.
[8] Chatterjee P, Roy D. Insight into the epigenetics of Alzheimers disease: a computational study from human interactome[J]. Curr Alzheimer Res, 2016, 13(12): 1385-1396.
[9] Najem D, Bamji-Mirza M, Yang Z, et al. Aβ-induced insulin resistance and the effects of insulin on the cholesterol synthesis pathway and Aβ secretion in neural cells[J]. Neurosci Bull, 2016, 32(3): 227-238.
[10] Kubota T, Matsumoto H, Kirino Y. Ameliorative effect of membrane-associated estrogen receptor G protein coupled receptor 30 activation on object recognition memory in mouse models of Alzheimers disease[J]. J Pharmacol Sci, 2016, 131(3): 219-222.
[11] 李波, 金尚丽. 血管危险因素与阿尔茨海默病患者认知功能下降的相关性[J]. 实用医学杂志, 2015, 31(2): 262-264.
[12] 李娅, 龙慧, 楚兰,等. 阿尔茨海默病与血管性危险因素关系研究: 中国学者海外报道[J]. 中国现代神经疾病杂志, 2015,15(7):518-523. LI Ya, LONG Hui, CHU Lan, et al. Studies on the association between Alzheimers disease and vascular risk factors: reports from China[J]. J Contemp Neurol Neurosurg, 2015, 15(7): 518-523.
[13] 何迎雪, 丛琳, 杜怡峰. 阿尔茨海默病患者睡眠障碍的临床特点及相关因素[J]. 山东大学耳鼻喉眼学报, 2015, 29(2): 1-8. HE Yingxue, CONG Lin, DU Yifeng. Clinical investigation of sleep disorders and related factors in Alzheimers disease[J]. J Otolaryngol Ophthal Shandong Univ, 2015, 29(2): 1-8.
[14] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimers disease at 25 years[J]. EMBO Mol Med, 2016, 8(6): 595-608.
[15] 王建枝,田青. Tau蛋白过度磷酸化机制及其在阿尔茨海默病神经元变性中的作用[J]. 生物化学与生物物理进展, 2012, 39(8): 771-777. WANG Jianzhi, TIAN Qing. Molecular mechanisms underlie Alzheimer-like Tau hyperphosphorylation and neurodegeneration[J]. Prog Biochem Biophys, 2012, 39(8): 771-777.
[16] Jaworski T, Kügler S, Van Leuven F. Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimers disease[J]. Int J Alzheimers Dis, 2010, pii: 573138. doi: 10.4061/2010/573138.
[17] Maphis N, Xu G, Kokiko-Cochran ON, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain[J]. Brain, 2015,138(Pt 6): 1738-1755.
[18] del Ser T, Steinwachs KC, Gertz HJ, et al. Treatment of Alzheimers disease with the GSK-3 inhibitor tideglusib: a pilot study[J]. J Alzheimers Dis, 2013, 33(1): 205-215.
[19] Beck SJ, Guo L, Phensy A, et al. Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimers disease[J]. Nat Commun, 2016, 7: 11483. doi: 10.1038/ncomms11483.
[20] Du H, Guo L, Fang F, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimers disease[J]. Nat Med, 2008, 14(10):1097-1105.
[21] Du H, Guo L, Wu X, et al. Cyclophilin D deficiency rescues Abeta-impaired PKA/CREB signaling and alleviates synaptic degeneration[J]. Biochim Biophys Acta, 2014, 1842(12 Pt A): 2517-2527.
[22] Guo L, Du H, Yan S, et al. Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimers neurons[J]. PLoS One, 2013, 8(1): e54914. doi: 10.1371/journal.pone.0054914.
[23] Gauba E, Guo L, Du H. Cyclophilin D promotes brain mitochondrial F1FO ATP synthase dysfunction in aging mice[J]. J Alzheimers Dis, 2017, 55(4): 1351-1362.
[24] Wang L, Guo L, Lu L, et al. Synaptosomal mitochondrial dysfunction in 5xFAD mouse model of Alzheimers disease[J]. PLoS One, 2016, 11(3): e0150441. doi: 10.1371/journal.pone.0150441.
[25] Du H, Guo L, Yan S, et al. Early deficits in synaptic mitochondria in an Alzheimers disease mouse model[J]. Proc Natl Acad Sci U S A, 2010, 107(43): 18670-18675.
[26] Swerdlow RH, Burns JM, Khan SM. The Alzheimers disease mitochondrial cascade hypothesis: progress and perspectives[J]. Biochim Biophys Acta, 2014, 1842(8): 1219-1231.
[27] Ellison EM, Abner EL, Lovell MA. Lovell, Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimers disease[J]. J Neurochem, 2017, 140(3): 383-394.
[28] Sanchez-Mut JV, Gräff J. Epigenetic alterations in Alzheimers disease[J]. Front Behav Neurosci, 2015, 9: 347. doi: 10.3389/fnbeh.2015.00347.
[29] Bernstein AI, Lin Y, Street RC, et al. 5-Hydroxymethylation-associated epigenetic modifiers of Alzheimers disease modulate Tau-induced neurotoxicity[J]. Hum Mol Genet, 2016, 25(12): 2437-2450.
[30] Eid A, Bihaqi SW, Renehan WE, et al. Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimers disease[J]. Alzheimers Dement(Amst), 2016, 2: 123-131. doi: 10.1016/j.dadm.2016.02.002.
[31] Morales I, Guzmán-Martínez L, Cerda-Troncoso C, et al. Neuroinflammation in the pathogenesis of Alzheimers disease. A rational framework for the search of novel therapeutic approaches[J]. Front Cell Neurosci, 2014, 8: 112. doi: 10.3389/fncel.2014.00112.
[32] Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimers disease mouse models[J]. J Exp Med, 2015, 212(3): 287-295.
[33] Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimers disease[J]. N Engl J Med, 2013, 368(2): 107-116.
[34] Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimers disease; A source of heterogeneity and target for personalized therapy[J]. Neuroscience, 2015, 302: 103-111.
[35] Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimers disease: evidence for NSAIDs and novel therapeutics[J]. Expert Rev Neurother, 2017, 17(1): 17-32.
[36] Cristóvão JS, Santos R, Gomes CM. Metals and neuronal metal binding proteins implicated in Alzheimers disease[J]. Oxid Med Cell Longev, 2016, 2016: 9812178. doi: 10.1155/2016/9812178.
[37] Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimers disease[J]. Neurochem Int, 2013, 62(5): 540-555.
[38] Southon A, Greenough MA, Ganio G, et al. Presenilin promotes dietary copper uptake[J]. PLoS One, 2013, 8(5): e62811. doi: 10.1371/journal.pone.0062811.
[39] Braidy N, Poljak A, Marjo C, et al. Metal and complementary molecular bioimaging in Alzheimers disease[J]. Front Aging Neurosci, 2014, 6: 138. doi: 10.3389/fnagi.2014.00138.

相关文章 15

[1]	闫鹏王蓉杜怡峰沈伦乾. 老年性痴呆患者尿中AD7c-NTP含量的研究[J]. 山东大学学报(医学版), 2209, 47(6): 106-.
[2]	黄玉真,吕琛,颜磊,李帅帅,张景雪,刘超,王银霞,桑岩岩,房鹛. 基于危险因素筛查的延续性院外管理对卵巢过度刺激综合征的预防效果[J]. 山东大学学报 (医学版), 2026, 64(4): 92-99.
[3]	逄锦宏,苏萍,乔俊鹏,陈巧巧,陈学禹,赵颖颖,施婕,孙晓茹,李秋春,何蕊言,范轶欧,迟蔚蔚. 老年人群可改变心血管危险因素聚集模式与脑卒中的关联[J]. 山东大学学报 (医学版), 2025, 63(9): 11-19.
[4]	张政,王建伟,杨玉娟,张宇,宋西成. 哮喘儿童2008及2019年免疫球蛋白E变化及相关危险因素[J]. 山东大学学报 (医学版), 2025, 63(7): 32-36.
[5]	李敬,郝盼盼. 急性心力衰竭患者出入院心率变化与预后相关性[J]. 山东大学学报 (医学版), 2025, 63(4): 75-82.
[6]	程震宇,来庆国,吴梦涛. 髂股静脉支架置入术后再狭窄的影响因素研究进展[J]. 山东大学学报 (医学版), 2025, 63(12): 112-117.
[7]	梁炎春,严莹,麦华希,姚书忠. 地诺孕素在子宫内膜异位症相关性疼痛中的治疗作用:从基础到临床[J]. 山东大学学报 (医学版), 2025, 63(10): 27-33.
[8]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[9]	王浙宇,许懿,赵昌波,杨硕菲,倪其泓,陈佳佺,王韦仑,李一男,郭相江,叶猛,张岚,薛冠华. 腹主动脉瘤腔内修复术后发生髂支闭塞的危险因素及处理对策[J]. 山东大学学报 (医学版), 2024, 62(9): 101-107.
[10]	郭鑫,孟君,郑世良,董秀红. 老年胃癌患者衰弱与人体成分的相关性[J]. 山东大学学报 (医学版), 2024, 62(4): 40-47.
[11]	李建,孙云. 新入维持性血液透析患者2年内死亡的危险因素[J]. 山东大学学报 (医学版), 2024, 62(4): 48-53.
[12]	宋甜田,李作坤,王书会. 个体化预测老年心脏瓣膜置换术后医院感染风险Nomogram模型的构建[J]. 山东大学学报 (医学版), 2024, 62(1): 48-56.
[13]	曲永强,赵泽宇,吴兴原,韩玮,段瑞生,李衍滨,李亨. 颈动脉分叉处支架置入术后严重持续性低血压的危险因素[J]. 山东大学学报 (医学版), 2023, 61(7): 78-82.
[14]	宋晗,王振华,韦铎亮,徐凯,李博文,赵鑫. 术前MELD分级对304例急性StandfordA型主动脉夹层患者术后早期结局的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 31-36.
[15]	张蒙,马伟. 1990—2019年中国人类免疫缺陷病毒/获得性免疫缺陷综合征流行趋势及疾病负担[J]. 山东大学学报 (医学版), 2023, 61(5): 84-89.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed